Vimarsana
Biggest News Aggregation in the World

Bend Points News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bend Points. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bend Points Today - Breaking & Trending Today

Finding the balance between access to, security of data in a borderless world - Vimarsana News

Finding the balance between access to, security of data in a borderless world

The global, borderless nature of business introduces risk as there are multiple applications, systems and end points that represent potential vulnerabilities, says Ryan Boyes, GRC officer at Galix.

RNA Interference With Zilebesiran for Mild to Moderate Hypertension - Vimarsana News

RNA Interference With Zilebesiran for Mild to Moderate Hypertension

This phase 2 randomized trial examines the antihypertensive efficacy and safety of different zilebesiran dosing regimens.

Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial | Cardiology | JAMA - Vimarsana News

Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial | Cardiology | JAMA

This randomized clinical trial examines the safety of the exclusion of aspirin as part of an antithrombotic regimen including a vitamin K antagonist with a full

Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension - Vimarsana News

Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension

This randomized clinical trial assesses the effect of 5 dosages of lorundrostat treatment vs placebo on 8-week systolic blood pressure change among adults with

FDA Approval Sought for Crovalimab for Paroxysmal Nocturnal Hemoglobinuria - Vimarsana News

FDA Approval Sought for Crovalimab for Paroxysmal Nocturnal Hemoglobinuria

The FDA has accepted a biologics license application seeking the approval of crovalimab for use in patients with paroxysmal nocturnal hemoglobinuria.